-

Biosynth Carbosynth Further Expands Life Sciences Platform with Acquisition of Aalto Bio Reagents

Addition of Aalto Bio Reagents expands Biosynth Carbosynth’s offer to its clinical diagnostics customers.

STAAD, Switzerland--(BUSINESS WIRE)--Biosynth Carbosynth (“Biosynth”), a supplier of critical materials to the life science industry, announces today the acquisition of Aalto Bio Reagents (“Aalto”), a leading developer and provider of biological materials to the in-vitro diagnostic (IVD) and vaccine development industry in the field of emerging disease.

The acquisition represents a further milestone in Biosynth’s development, which broadens its capabilities and offering to the IVD industry. Aalto’s product portfolio includes an extensive range of proteins, antigens, antibodies, disease state human plasma and biospecimens used by the leading diagnostics and vaccine development companies around the world working on emerging diseases and disease variants.

Dr. Urs Spitz, CEO and President of Biosynth, said, “This acquisition marks the next phase of our ambitious journey to become a leading global supplier and partner to the biopharma and diagnostics industries. It allows us to offer an expanded range of products to our IVD customers including complex biochemicals, peptides and biological materials. We are pleased to welcome Aalto and its employees and look forward to working with them to continue to grow our offering to the diagnostics industry.”

Philip Noone, CEO of Aalto, added, “We are delighted to be joining forces with Biosynth, a world-renowned supplier with a broad portfolio of critical products and services across biopharma and diagnostics. Aalto’s industry leading products and key focus on emerging disease are an excellent fit with Biosynth’s products, and we see huge opportunities for the platform to be at the forefront of developing new innovative products and supplying our customers with an even greater scale and diversity of products they need to solve the diseases of the future.”

https://www.carbosynth.com/

Contacts

Media
Biosynth Carbosynth
Aimee Cossins
+44 7984 525560
marketing@biosynth-carbosynth.com

Biosynth Carbosynth


Release Versions

Contacts

Media
Biosynth Carbosynth
Aimee Cossins
+44 7984 525560
marketing@biosynth-carbosynth.com

More News From Biosynth Carbosynth

Biosynth Expands Berlin Site with a New Commercial Bioconjugation Suite

STAAD, Switzerland--(BUSINESS WIRE)--Biosynth, a leading developer and supplier of critical raw materials and services for life sciences and diagnostics, is pleased to announce the opening of its expanded GMP bioconjugation facility at its existing Berlin site. This strategic expansion significantly enhances Biosynth's specialized manufacturing capabilities in conjugate vaccines and conjugate drugs, activated PEGs, and polymer-based drug delivery excipients as part of its global manufacturing n...

Biosynth Names Matt Gunnison as CEO, Kieran Murphy Appointed as Chairman

STAAD, Switzerland--(BUSINESS WIRE)--Biosynth, a global supplier of critical raw materials and services to the life sciences industry, today announced that its Board of Directors has appointed Matt Gunnison as the company's new Chief Executive Officer and a member of the Board of Directors, effective immediately. The Board has also appointed Kieran Murphy as Chairman, effective as of the same date. Matt Gunnison will succeed Urs Spitz, under whose guidance Biosynth has achieved remarkable growt...

Opening of Biosynth Biological Technology; a new Cutting-Edge Facility at Lifebay in Suzhou, China

STAAD, Switzerland--(BUSINESS WIRE)--Biosynth, a leading developer and supplier of critical raw materials and services for diagnostics, vaccines, and pharmaceutical industries, is pleased to announce the opening of their Biosynth Biological Technology site at Lifebay, an innovative technology park in Suzhou, China. This new site houses state-of-the-art facilities including a Bio-laboratory which significantly enhances capabilities for internal project development initiatives and material supply...
Back to Newsroom